Joseph Rossano, MD, MS, is the co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS

Mavacamten exhibited greater reduction of left ventricular outflow compared to placebo in adolescent patients with 

obstructive hypertrophic cardiomyopathy (HCM)

, according to data from the SCOUT-HCM trial.

American College of Cardiology (ACC) Scientific Sessions 2026

 in New Orleans, Louisiana, by Joseph Rossano, MD, MS, co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

“Prior to this, what we used for children was really aimed at helping to alleviate their symptoms, and it wasn’t actually based on very strong evidence that it was helpful for those patients,” Rossano told 

 in an exclusive interview. “It’s really extrapolated from what we use for adult patients. To see such dramatic reductions in the gradients, as well as the improvements in the secondary endpoints, is really encouraging.”

SCOUT-HCM is an ongoing phase 3, double-blind, randomized, placebo-controlled trial consisting of active-treatment and long-term extension periods. Patients were eligible for inclusion if they were aged 12 to <18 years and had received a diagnosis of HCM, which was defined as a maximal left ventricular wall thickness of ≥15 mm (or ≥13 mm with a family history of HCM), had a left ventricular outflow tract pressure gradient during the Valsalva maneuver of ≥30 mmHg, or had a maximal left ventricular outflow tract gradient of ≥50 mmHg, among other criteria. Patients with HCM phenocopies, such as Noonan syndrome and Fabry disease, were excluded.

After confirming eligibility via a 5-week screening period, Rossano and colleagues randomly assigned enrolled patients in a 1:1 ratio to receive mavacamten or placebo during the 28-week treatment period. Mavacamten was started at a once-daily dose of 5 mg in patients with body weight of ≥45 kg (99.2 lb) or 2.5 mg in patients with a body weight of 35 to <45 kg (77.2 to <99.2 lb). This dose could be adjusted down at weeks 5 and 9 or up at weeks 12 and 24 by 1 dose level, based on electrocardiographic assessment of the Valsalva left ventricular outflow tract gradient and LVEF.

The study’s primary endpoint was the change in left ventricular outflow tract pressure gradient provoked by the Valsalva maneuver from baseline. Secondary endpoints included the change from baseline in resting and postexercise left ventricular outflow tract gradients, the maximal left ventricular wall thickness, and the ratio of early mitral inflow velocity to mitral annular early diastolic velocity.

A total of 65 patients were screened for eligibility – of these, 44 were included and assigned to the mavacamten arm (n = 23) or the placebo arm (n = 21). All patients in the mavacamten arm had a dose adherence of ≥80%. Over the course of the study, mean Valsalva left ventricular outflow tract gradient decreased from 78.4 +/- 34.1 mmHg at baseline to 29 +/- 18.3 mmHg at week 28 in the mavacamten group (least-squares mean change, -48.5 mmHg; 95% CI, -63 to -34). The placebo arm exhibited a decrease from 80.8 +/- 47.4 mmHg to 72.7 +/- 40.1 mmHg (least-squares mean change, -0.5 mmHg; 95% CI, -18.7 to 17.6). This corresponded to a significant difference of -48 mmHg (95% CI, -67.7 to -28.3).

Rossano and colleagues reported adverse events in 18 patients (78%) in the mavacamten group versus 17 (81%) in the placebo group. The former saw 2 patients with serious adverse events – 1 patient had 2 episodes of syncope, and the other had an inappropriate shock from an implantable cardioverter-defibrillator. Among the placebo recipients, 2 patients had serious adverse events – 1 had chest pain, and the other had depression with suicidal ideation.

“Importantly, there were really no safety issues,” Rossano said. “We think the medication can be used safely in patients with pretty significant disease. Are there patients who may benefit more than others? Absolutely, that may be the case. I think we just need further study in larger populations over longer periods to try to sort that out.”

Editors’ Note: Rossano reports disclosures with Bristol Myers Squibb, AskBio, Astellas, Merck, and Bayer.

Rossano J, Canter E, Wolf C, et al. Mavacamten in Symptomatic Adolescent Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the Phase 3 Scout-HCM Trial. Abstract presented at the American College of Cardiology Scientific Sessions 2026 in New Orleans, LA. March 28-30, 2026.

Rossano JW, Canter C, Wolf CM, et al. Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy. 

Videos

Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten’s comparative superiority in reducing left ventricular outflow.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

Andres Gelrud, MD, is a gastroenterologist at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida

Beyond Chronic Pancreatitis, Rethinking Who Gets EPI and How We Treat It, With Andres Gelrud, MD

remains a misunderstood disease, leading to gaps and unmet needs in patient care across multiple etiologies, with clinicians reassessing the future of the therapeutic landscape.

Many clinicians lack awareness of how far-reaching EPI can be, mainly focusing on its presentation in patients with chronic pancreatitis, pancreatic cancer, post–pancreatic resection, and cystic fibrosis. There's an unmet need in identifying EPI in patients with type 1 and 2 diabetes, post-gastric resection and gastric bypass patients, celiac disease, and severe acute pancreatitis, who are at an increased risk.

"The ones that are frequently left behind and that we don't tend to think too much about are patients, for example, with diabetes, type one, type two, patients with gastric resections, patient with gastric bypass that they have a completely normal looking and functional pancreas, but for other reasons, you know, they're developing exocrine pancreatic insufficiency," said Andres Gelrud, MD, a gastroenterologist at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida, in an interview with HCPLive. "So these are conditions actually that we don't tend to think about, but it's very important, because now we do recognize them as patients that may have exocrine pancreatic insufficiency, and starting treatment will have a major impact in their quality of life."

 due to its symptoms overlapping with common gastrointestinal disorders, including irritable bowel syndrome and celiac disease, which include bloating, diarrhea, and weight loss. Patients may wait years before approaching a doctor about these symptoms due to their non-specificity and embarrassment to broach the subject of GI issues. Often, symptoms will not manifest until significant pancreatic damage has already occurred, leading to a harder-to-treat patient.

commonly utilized test for diagnosing EPI i

s the fecal elastase-1 (FE-1). However, this test lacks sensitivity for mild to moderate cases, and furthermore, false positives are common when stool is watery or diluted, underscoring the need to interpret results in clinical context. For context, an FE-1 result < 200 µg/g is abnormal, with values < 100 µg/g indicating a high likelihood of EPI and levels between 100 to 200 µg/g indeterminate.

Furthermore, clinicians who treat EPI are witness to the major pill burden their patients face. Right now, pancreatic enzyme replacement therapy has been supported as the best available option, but patients do not find it ideal.

"One of the biggest unmet needs that I see is that patients frequently complain of the number of pills that they have to take, the size of the pill that they have to take,” said Gerlund. “This is an issue that I tend to hear over and over and over."

To address this pill burden, the field would have to discover new pharmaceutical formulations to make disease management easier for patients. 

Barkin JA, Delk TB, Powell VJ. Symptoms, burden, and unmet needs of patients living with exocrine pancreatic insufficiency: a narrative review of the patient experience. 

https://doi.org/10.1186/s12876-024-03188-w

Radlinger B, Ramoser G, Kaser S. Exocrine Pancreatic Insufficiency in Type 1 and Type 2 Diabetes. 

https://doi.org/10.1007/s11892-020-01304-0

Epidemiology, evaluation and management of exocrine pancreatic insufficiency (EPI). American Gastroenterological Association. Published April 2, 2024. 

https://gastro.org/clinical-guidance/epidemiology-evaluation-management-exocrine-pancreatic-insufficiency/

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face. 

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London.

Late-Onset Depression Linked to Increased Dementia Risk, With Lingfeng Xue, PhD

Late-onset depression was associated with poorer performance in fluid intelligence and visuospatial memory, as well as a greater risk of incident dementia, in older adults with 

, Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London, discussed the implications of these findings.

“The relationship between late-onset depression and…dementia can be complicated,” Xue said. “The depressive symptoms [can represent a] prodrome of dementia or independently as a risk factor of dementia. These are 2 valid theories, and they both have evidence…there's no exclusive or established theory for 1 against another.”

The analysis evaluated 75,064 adults aged ≥ 60 years from the UK Biobank with linked primary care data, comparing cognitive outcomes and dementia incidence across depression subtypes defined by age at onset.1 Participants with late-life depression with late onset (LLD-LO), defined as the first depressive episode after age 50 years, demonstrated significantly worse performance in fluid intelligence and visuospatial memory compared with both depression-free controls and those with earlier-onset depression. Over a median follow-up of 13.69 years, LLD-LO was associated with an increased risk of incident dementia, with hazard ratios ranging from 1.42 to 1.52 across adjusted models.1

Impairments in fluid intelligence and visuospatial memory partially mediated dementia risk, accounting for 3.1% (95% CI, 1.2% to 5.0%) and 1.4% (95% CI, 0.4% to 2.5%) of the association, respectively.1 Xue noted that such deficits may be detectable in midlife and should prompt further evaluation.

“Any mid-age cognitive loss warrants attention in… real-world practice,” he said, referencing commonly used tools such as the Wechsler Adult Intelligence Scale for reasoning and computerized tasks for visuospatial assessment.

The reported hazard ratio of approximately 1.4 to 1.5 indicates a 40–50% relative increase in dementia risk among individuals with late-onset depression. Xue said this aligns with prior evidence identifying depression as a modifiable risk factor for dementia. He added that first-onset depression after 50 years old should prompt clinicians to consider additional cognitive assessment and longitudinal monitoring.

The study’s use of age 50 years as a cutoff for late-onset depression was intended to increase sensitivity for detecting early cognitive changes. Sensitivity analyses suggested this threshold captured associations with impairment more effectively than higher cutoffs.

Xue cautioned against rigid clinical interpretation of this boundary. Rather, the findings serve more as a reminder that mid-to late-life depression onset is associated with later cognitive decline.

The findings support integrating cognitive screening into the evaluation of patients presenting with first-onset depression in mid- to late life. Xue highlighted the importance of considering both psychiatric and neurological pathways when assessing these patients, particularly given the potential for early cognitive changes to precede clinically recognized dementia.

“The onset of depression after 50 is multi-driven, so the clinician should consider various factors from multiple dimensions into consideration,” Xue said.

Xue L, Bocharova M, Young AH, Aarsland D. Late-onset depression predicts cognitive impairment and subsequent dementia among older adults with major depressive disorder: findings from UK Biobank and primary care linked data. 

. 2026;12(2):e88. Published 2026 Mar 10. 

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

Next Steps for Upadacitinib in Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Upadacitinib’s impact over 48 weeks on patients with non-segmental vitiligo is highlighted in recent findings presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

, with the investigators identifying no new safety signals or major adverse cardiovascular events (MACE) over this treatment period.

These findings from the Viti-Up-1 and Viti-Up-2 studies led to an interview on-site at AAD between the 

 team and Viti-Up trial investigator Thierry Passeron, MD, PhD, professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

 In this additional segment, Passeron was asked several additional questions about the data, including his view on the future of this research. 

“In fact, we are looking forward to the longer-term results, because now the study is continuing in open label for two years,” Passeron explained. “After two years, the patient who wants to can combine with narrow band UVB. We are already seeing, in my department, that the patients continue to grow. But while we must wait for the results, and I'm quite optimistic also that when we will combine with narrow band UVB, it will boost the recommendation.”

Passeron was also asked how he might counsel patients who are seeking complete clearance of their non-segmental vitiligo. He stressed the importance of managing the expectations of such patients, noting vitiligo is not the same as psoriasis or atopic dermatitis. Passeron noted one cannot expect to have clearance 16 or even 24 weeks, describing monotherapy as time-consuming.

Later, Passeron was also asked about whether there had been any differences in racial subgroups observed within the Viti-Up studies. He noted there was not yet a subgroup analysis, though such data may be released in time. He also noted the importance of looking at the difference results among younger versus older patients.

“I'm working on vitiligo for more than 25 years, and we are very excited for the patients already,” Passeron said. “…Already, the results for [upadacitinib] are very good.”

For any additional information on these new data or their discussion with Passeron, view his full interview segment posted above.

Passeron is a consultant for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Calypso, Galderma, Incyte Corporation, Janssen, Eli Lilly, Novartis, Pfizer, Roivant, UCB, and VYNE Therapeutics. He has received grants and/or honoraria from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme/Sanofi, GlaxoSmithKline, Incyte Corporation, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Roivant, Sun Pharmaceuticals, Takeda, UCB, and VYNE Therapeutics. He is the cofounder of NIKAIA Pharmaceuticals and founder of SUNLUTION, and has patents on WNT agonists or GSK3b antagonist for repigmentation of vitiligo and the use of CXCR3B blockers in vitiligo.

Passeron T, Prajapati V, Seneschal J, et al. Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo: Results of Two Phase 3 Studies (Viti-Up). Presented at: 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO.

Passeron T. Upadacitinib Safe, Effective Over 48 Weeks for Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD. HCPLive. March 30, 2026. Accessed April 1, 2026. 

https://www.hcplive.com/view/upadacitinib-safe-effective-48-weeks-non-segmental-vitiligo-thierry-passeron-md-phd

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Food and Drug Administration has approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight with weight-related medical problems. The once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist can be taken any time of the day without restrictions on food and water intake.

As described in an April 1, 2026, release from the Company, when used alongside a reduced-calorie diet and increased physical activity, orforglipron helps individuals lose excess body weight and keep the weight off. In the ATTAIN-1 clinical trial, adults taking orforglipron lost an average of 27 pounds on the highest dose.

"People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, said in a statement. "With [orforglipron], we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day."

Orforglipron is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

Its use in overweight and obesity was explored in the ATTAIN Phase 3 global clinical development program, which has enrolled > 4500 people with obesity or overweight across 2 global registration trials. ATTAIN-1 is a phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with ≥ 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes.

The trial randomized 3127 participants across the US, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in body weight reduction from baseline after 72 weeks.

ATTAIN-2 is a phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized > 1600 participants across the US, Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks.

In the ATTAIN-1 trial, individuals taking the highest dose of orforglipron and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo. Participants taking orforglipron, regardless of trial completion, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo.

Positive topline results from ATTAIN-2 were announced in August 2025 and showed all 3 doses of orforglipron met the trial’s primary and all key secondary endpoints, delivering significant weight loss, meaningful A1C reductions, and improvements in cardiometabolic risk factors at 72 weeks in adult patients with with obesity or overweight and type 2 diabetes.

In the ATTAIN program, orforglipron also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses.

"There is no single path that works for everyone living with overweight or obesity," said Joe Nadglowski, president and CEO of the Obesity Action Coalition. "New treatment options expand choice and help more people find care that fits their lives, their goals and where they are in their journey – whether they're just starting to explore treatment or looking for a different long-term approach."

Lilly. FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions/ April 1, 2026. Accessed April 1, 2026. 

https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

Brooks A. Orforglipron Delivers Weight Loss, A1C Reductions in Phase 3 ATTAIN-2 Trial. August 26, 2025. Accessed April 1, 2026. 

https://www.hcplive.com/view/orforglipron-delivers-weight-loss-a1c-reductions-in-phase-3-attain-2-trial

Articles

FDA approved Lilly’s orforglipron (Foundayo), a once-daily, non-peptide oral GLP‑1 receptor agonist for chronic weight management in adults with obesity or overweight plus weight-related comorbidities, usable without food or water restrictions. In the 72‑week, global, randomized ATTAIN‑1 trial (n=3127; no diabetes), highest-dose participants remaining on therapy lost 27.3 lb (12.4%) versus 2.2 lb with placebo. Across ATTAIN, treatment improved waist circumference, non‑HDL cholesterol, triglycerides, and systolic blood pressure. ATTAIN‑2 enrolled >1600 adults with obesity/overweight and type 2 diabetes.

The Agency approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight. It can be taken any time of the day without restrictions on food and water intake.

FDA News

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions

Christopher Chan, MD, is director of the division of nephrology, professor of medicine, and R Fraser Elliott Chair in Nephrology at Toronto General Hospital, University Health Network.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Entering A New Era of Flexible Dialysis Care, With Christopher Chan, MD

Sofia Holmqvist-Jämsén, PhD, from the University of Helsinki

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Respiratory Allergies Linked to Frequent Vocal Symptoms, With Sofia Holmqvist-Jämsén, PhD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

Learn smarter oral iron dosing: once daily or every other day to cut GI side effects, boost absorption, and avoid tea/coffee.

Video Series

Oral Iron — Formulation Selection, Dosing Frequency, and Absorption Optimization 

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Podcasts

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Type 2 Diabetes

Type 1 Diabetes

Don’t Miss a Beat

The Don't Miss a Beat Podcast is a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Don't Miss a Beat: MRA Updates at ACC 2026 Scientific Sessions

Professor and Chair of the Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases and in the Peter O'Donnell Jr. School of Public Health at UT Southwestern Medical Center in Dallas

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Evolving Research Landscape Drives Progress in CLE at AAD 2026

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.

AMETHYST Phase 3 and Remaining Questions Surrounding Litifilimab in CLE

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Potential of Targeting BDCA2 in Cutaneous Lupus Erythematosus Management

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Navigating Multidisciplinary Care for CLE in an Evolving Landscape

Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.

Latest News

SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS

Beyond Chronic Pancreatitis, Rethinking Who Gets EPI and How We Treat It, With Andres Gelrud, MD

Late-Onset Depression Linked to Increased Dementia Risk, With Lingfeng Xue, PhD

Next Steps for Upadacitinib in Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions